Bharat Parenterals gets DCGI approval for favipiravir oral suspension

Bharat Parenterals gets DCGI approval for favipiravir oral suspension

Bharat Parenterals’ favipiravir oral suspension has recently received approval from the Drugs Controller General of India (DCGI) for treatment of COVID-19 patients.

The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.

Favipiravir is an antiviral drug approved in Japan in 2014 for the treatment of new or re-emerging influenza virus infections.